Orthofix Medical Yönetim

Yönetim kriter kontrolleri 0/4

Orthofix Medical CEO'su Massimo Calafiore, Jan2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.003% doğrudan sahiptir ve bu hisselerin değeri $ 18.89K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.7 yıl ve 1.4 yıldır.

Anahtar bilgiler

Massimo Calafiore

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.003%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.4yrs

Son yönetim güncellemeleri

Recent updates

Orthofix Medical (NASDAQ:OFIX) Is In A Good Position To Deliver On Growth Plans

Nov 01

CEO

Massimo Calafiore (52 yo)

less than a year

Görev süresi

Mr. Massimo Calafiore is President, CEO & Director of Orthofix Medical Inc. from January 8, 2024 and as Interim President of Global Spine from January 10, 2024. Mr. Massimo Calafiore was the Chief Executiv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Geoffrey Gillespie	VP & Corporate Controller	3.5yrs	US$887.05k	0.0050% $ 36.1k
Massimo Calafiore	President	less than a year	Veri yok	0.0026% $ 18.9k
Julie Andrews	Chief Financial Officer	less than a year	Veri yok	Veri yok
Aviva McPherron	President of Global Operations & Quality	less than a year	Veri yok	Veri yok
Julie Dewey	Chief Investor Relations & Communications Officer	less than a year	Veri yok	Veri yok
Jill Mason	Interim Chief Ethics & Compliance Officer and VP of Corporate Counsel	no data	Veri yok	Veri yok
J. Cedron	Chief Legal Officer & Corporate Secretary	less than a year	Veri yok	Veri yok
Stephanie Walsh	Chief Human Resources Officer	less than a year	Veri yok	Veri yok
Ehab Esmail	Senior Vice President of Global Quality	5.8yrs	Veri yok	Veri yok
Tyler Lipschultz	President of Global Biologics	1.8yrs	Veri yok	Veri yok
Beau Standish	President of Global Enabling Technologies	no data	Veri yok	Veri yok
Lucas Vitale	Chief People & Business Operations Officer	less than a year	Veri yok	Veri yok

0.7yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: OFIX 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Massimo Calafiore	President	less than a year	Veri yok	0.0026% $ 18.9k
John Henneman	Independent Director	1.8yrs	US$355.42k	0.090% $ 649.3k
Alan Bazaar	Independent Director	less than a year	US$300.00k	0% $ 0
Jason Hannon	Independent Director	4.4yrs	US$376.25k	0.012% $ 86.3k
Charles Kummeth	Independent Director	less than a year	US$300.00k	0.039% $ 283.0k
Michael Finegan	Independent Chair of the Board	less than a year	US$300.00k	0% $ 0
Michael Paolucci	Independent Director	8.7yrs	US$376.25k	0.032% $ 227.7k
Shweta Maniar	Independent Director	1.8yrs	US$355.42k	0.015% $ 108.0k
Wayne Burris	Independent Director	1.4yrs	US$539.70k	0.017% $ 120.4k

1.4yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: OFIX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Orthofix Medical Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

Orthofix Names Stephanie Walsh as Chief Human Resources Officer

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Recent updates

Third quarter 2024 earnings: EPS misses analyst expectations

Orthofix Medical Inc. Reiterates Earnings Guidance for Full Year 2024

Levi & Korsinsky, LLP Notifies Investors in Orthofix Medical Inc. of A Class Action Securities Law

Orthofix Medical Inc. to Report Q3, 2024 Results on Nov 07, 2024

Bronstein, Gewirtz & Grossman, LLC Files Lawsuit Against Orthofix Medical Inc. and Seaspine Holdings Corporation

No longer forecast to breakeven

Scott+Scott Attorneys At Law LLP Files Securities Class Action Lawsuit in the United States District Court for the Eastern District of Texas Against Orthofix Medical, Inc

Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

Consensus EPS estimates fall by 24%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthofix Medical Inc. Revises Revenue Guidance for the Full Year 2024

Orthofix Names Stephanie Walsh as Chief Human Resources Officer

Orthofix Medical Inc. to Report Q2, 2024 Results on Aug 06, 2024

Orthofix Medical Inc. Announces First Implant of Fitbone Transport and Lengthening System

Orthofix Medical Inc.(NasdaqGS:OFIX) dropped from Russell 2000 Value-Defensive Index

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc. Announces FDA 510(K) Clearance for the Rodeo Telescopic Nail

Orthofix Medical Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 21% to US$21.80

Consensus EPS estimates upgraded to US$1.27 loss

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Orthofix Medical Inc. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Profitability

Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer

Orthofix Medical Inc. Announces Board Resignation

Orthofix Medical Inc. Appoints Lucas Vitale as Chief People and Business Operations Officer

Consensus EPS estimates fall by 12%

Full year 2023 earnings: EPS misses analyst expectations

Orthofix Medical Inc. Provides Earnings Guidance for the Year 2024

Orthofix Medical Inc. to Report Q4, 2023 Results on Mar 05, 2024

Orthofix Medical Inc. Names Massimo Calafiore as President and Member of the Board of Directors Effective Immediately

Orthofix Medical Inc. Appoints Julie Andrews as Chief Financial Officer

Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis

Orthofix Medical Inc. Announces Board Changes

Orthofix Medical Inc. Appoints Massimo Calafiore as Chief Executive Officer, Effective in Early 2024

Consensus EPS estimates upgraded to US$3.50 loss, revenue downgraded

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Orthofix Medical Inc. Announces Full Commercial Launch of the Waveform L Interbody System for Lateral Lumbar Fusion Procedures

Orthofix Medical Inc. to Report Q3, 2023 Results on Nov 08, 2023

Orthofix Medical Inc. Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for Use in Spine and Orthopedic Procedures

Orthofix Medical Inc. Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures

Independent Director recently bought US$101k worth of stock

Orthofix Medical Inc. Announces Management Appointments

Orthofix Medical Inc. Announces Management Changes

Price target decreased by 11% to US$29.00

Consensus EPS estimates fall by 12%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Orthofix Medical Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 12% to US$32.67

Orthofix Medical Inc. Introduces New Phantom and Tornado Hins for Truelok Ring Fixation Systems

Orthofix Medical Inc. Announces Changes to Board of Directors

Orthofix Medical Inc Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody

Orthofix Medical Inc. Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc with Other Clinical and Scientific Abstracts At the Isass Annual Meeting

President of Global Spine Business recently sold US$157k worth of stock

President of Global Spine Business notifies of intention to sell stock

Consensus EPS estimates fall by 81%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthofix Medical Inc. Revises Sales Guidance for the Year 2023

Consensus revenue estimates decrease by 18%

Full year 2022 earnings: EPS misses analyst expectations

High number of new directors

Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System

Orthofix Medical Inc. Provides Unaudited Preliminary Net Sales Results Fourth Quarter and Full Year Ended December 31, 2022

Orthofix Medical Inc. Announces CEO Changes